-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KGv/LgywZvonViaj7GRApz6cevMYb9uZRaAm/5D/0kDwIp4iZvtoTTc7Y5O3H4lk
 9aoTcPYFmJSjhyUesGjwDA==

<SEC-DOCUMENT>0001193125-09-018650.txt : 20090204
<SEC-HEADER>0001193125-09-018650.hdr.sgml : 20090204
<ACCEPTANCE-DATETIME>20090204143621
ACCESSION NUMBER:		0001193125-09-018650
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090130
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090204
DATE AS OF CHANGE:		20090204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		09567976

	BUSINESS ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 OR 15(d) of The Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported) January&nbsp;30, 2009 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>PSIVIDA CORP. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in Its Charter) </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-51122</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>26-2774444</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>400 Pleasant Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Watertown, MA 02472 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(617) 926-5000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not applicable </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;30, 2009, the Company&#146;s Board of Directors appointed Dr.&nbsp;Paul Ashton, age 48, to serve as President and Chief Executive Officer
(&#147;CEO&#148;) of the Company. Dr.&nbsp;Ashton served at the Company as Managing Director since January&nbsp;2007 and as Executive Director of Strategy from December&nbsp;2005 to January&nbsp;2007. From 1996 until its acquisition by the Company
in December&nbsp;2005, Dr.&nbsp;Ashton was the President and Chief Executive Officer of Control Delivery Systems, Inc., a drug delivery company that he co-founded in 1991. Dr.&nbsp;Ashton previously was a joint faculty member in the Departments of
Ophthalmology and Surgery at the University of Kentucky, served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman-La-Roche. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;7.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regulation FD Disclosure </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;2, 2009, the Company
issued a press release announcing Dr.&nbsp;Ashton&#146;s appointment as President and CEO. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A copy of the press release is furnished with this Form 8-K and
attached hereto as Exhibit 99.1. Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities under that
Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>(d) <U>Exhibits</U>. </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:11pt"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press release of pSivida Corp. dated February&nbsp;2, 2009</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>PSIVIDA CORP.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date: February&nbsp;4, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Michael J. Soja</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Michael J. Soja, Vice President, Finance and CFO</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B><U>Exhibit 99.1 </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g47936ex991.jpg" ALT="LOGO"> </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Media RELEASE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>February&nbsp;2, 2009</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>pSivida Corp. names Paul Ashton, Ph.D. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>President and Chief Executive Officer </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Watertown, MA &#150; February&nbsp;2, 2009 &#150; pSivida Corp.
(NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced that Paul Ashton, Ph.D. has been named President and Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Dr.&nbsp;David&nbsp;J. Mazzo, Non-executive Chairman, pSivida Corp said, &#147;The Board of Directors is confident in Paul&#146;s ability to continue to provide strategic leadership and vision as the company advances its portfolio of drug
delivery products.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Ashton joined pSivida in December 2005 following the acquisition of Control Delivery Systems (CDS) where he was
co-founder, President, CEO, and a member of the Board of Directors. Dr.&nbsp;Ashton was named Managing Director of pSivida Corp. in January 2007 and currently serves on the Company&#146;s Board of Directors. Before co-founding CDS, Dr.&nbsp;Ashton
was a joint faculty member in the Departments of Ophthalmology and Surgery at the University of Kentucky, served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman-La-Roche. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;pSivida is a world leader in the development of miniaturized, injectable, drug delivery systems for the eye,&#148; stated Dr.&nbsp;Ashton. &#147;The Company&#146;s
strategy is to develop specialty pharmaceuticals in the ophthalmic market and to pursue non-ophthalmic applications via partnering. I am honored to be named President and Chief Executive Officer.&#148; </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Released by:</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>pSivida Corp.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Brian Leedman</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Vice President, Investor Relations</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">pSivida Corp.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Tel:
+61 8 9227 8327</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">brianl@psivida.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>US Public Relations</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Beverly Jedynak</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">President</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Martin E. Janis &amp; Company, Inc</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Tel: +1 (312) 943 1100 ext. 12</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">bjedynak@janispr.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About pSivida Corp. </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">pSivida is a world leader in the development of miniaturized, injectable, drug delivery systems for the eye.
pSivida has two products approved by the Food and Drug Administration (FDA): Retisert<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> to treat uveitis and Vitrasert<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> for
treating AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch&nbsp;&amp; </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Lomb Incorporated. pSivida has one product in fully recruited Phase III clinical trials: Iluvien&#153;, which delivers fluocinolone acetonide (FA) for the
treatment of diabetic macular edema (DME), formerly known as Medidur FA for DME. pSivida has licensed certain drug delivery technology to Alimera Sciences, Inc. for the development of Iluvien and certain other ophthalmic products. pSivida has a
worldwide collaborative research and license agreement with Pfizer Inc. under which Pfizer may develop additional ophthalmic products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">pSivida owns the
rights to develop and commercialize a modified form of silicon known as BioSilicon&#153;, which has potential therapeutic applications. The most advanced BioSilicon product candidate, BrachySil&#153;, delivers a therapeutic P32, a radioactive form
of phosphorus used to treat cancer, directly to solid tumors. pSivida completed an initial safety and efficacy clinical trial of BrachySil for the treatment of pancreatic cancer and has commenced a dose-ranging clinical trial. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">pSivida&#146;s intellectual property portfolio consists of 45 patent families, over 100 granted patents, including patents accepted for issuance, and over 200 patent
applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe
may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the forward-looking statements: maintaining key collaboration agreements with Alimera and Pfizer;
uncertainties regarding the achievement of milestones and other contingent contractual payment events; failure to prove safety and efficacy of Iluvien or BrachySil; inability to raise capital; continued losses and lack of profitability; inability to
derive revenue from Retisert; termination of license agreements; inability to pay any registration penalties; inability to develop or obtain regulatory approval for new products; inability to protect intellectual property or infringement of
others&#146; intellectual property; inability to obtain partners to develop and market products; competition; risks and costs of international business operations; manufacturing problems; insufficient third-party reimbursement for products; failure
to retain key personnel; product liability; failure to comply with laws; failure to achieve and maintain effective internal control over financial reporting; impairment of intangibles; volatility of stock price; possible dilution through exercise of
outstanding warrants and stock options or future stock issuances; possible influence by Pfizer; and other factors that may be described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. We do not undertake to publicly update or revise our forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied in such
statements will not be realized. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g47936ex991.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g47936ex991.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0"T`P$1``(1`0,1`?_$`+\```$#!0$!`0``````
M```````'"`D!`@,&"@0+!0$``0,%`0$```````````````4&!P$"`P0("0H0
M```&`0,"`P0&!P,-``````$"`P0%!@<`$0@A$A,5"3%!%!9182(R&`IQD;$C
M)!<9@3.$\*'!\4)RLG.S-'6V.!$``0($!`0"!@<&!`4%`````0(#`!$$!2$Q
M$@9!41,'(@AA<8&1,A3PH;'!0A4)X5)B<B,6T?$S%X*RPC0U<T1D=+3_V@`,
M`P$``A$#$0`_`._C1!!H@@W#Z=4!!$QE!!H!!R@@WU6"&F\H>:''[B7%Q:N6
MK@H:VV@Y6E!Q)2HUW=<QY*E%%!20BZ'C>!*YL,VJLM]@7`II,D3?WRR8==9F
MJ9VIF@)_I_O9`?Y"&MN/>-CVN@?F+P^:4)H80.H^Z<@E#0QQ.&HR$\)PT^-G
MO5!Y/$).P#7%WIWXO>_Q$&TR%5&_(3D_*L3A_#O+!5"2\+BG'!W!=C"Q55EW
MS<1[5=C`(:V&Q1,N3EU2``3.0PX3_;#4#_<S<32GZ$TNW[>H30%M&JK)3`FX
MV2&D!7(S6D@SPQC+Z;N>>2F1[WS3PER&NE=S"?BMG"*Q;5,[5ZE1^/RY`%_6
M0FYZ#F:S"KN(%M/4TYFI71F@@!#/.P_<)0,-:QMIM"'FTZ4K$],R9##'Z_;&
MQV\N^XJZJNUEW$ZFM3;ZOHIJ@A#1<.:DEM'A&C`3SYQ*V3J4/[?U[CO_`)]:
M$P<1E$E@@Y99>["+M$5@T00:((-$$4W#Z0U0$'*#T1758(-$$&B"#1!!H@@T
M00:((-$$&B"+3"(;;!OUZA]6PZL<)""4@J5P'TRBHEC/E"(Y)R\ZQU))I.<<
MW6PP@1Q7[JQ5]LR<1[(04=`LU5(Y<MU%7*#=MXHD*(B)#!MN.^N:>]7F(JNR
M]U2W<-IWZY;333!U^Z4A8Z#,R9ME+BTK6H`3(3B9@)!QDK6ZTBY(&AQM+BL-
M*OB/LS^J-FKF2JK;*:>]5MTM,0B3%X[528-5595-2/147=1IXT/XGS1/M[00
M$.XYA+V[@8!%][*[R;#[B=N!W3V94.UFVFZ=QU:&6RJH26QJ6PJG1-77'!OX
MES&F8(C"];GZ)[Y5X%*N!.1!Y'EZ81AYS'Q)&+BUDV5[C'12$,+61J2[%R!#
M!N4QD'+I)4"F]P[;#KFB]?J)^7S;54+??6-T4%<I`7TGK4XPO220%:'%H)22
MD@*`D2")S$*C&U;K6-!^GZ;C)R(5,>^7U0FV4,NY'S]5DJ+Q,R`3#]XL3EPR
M6RK?<+S608FMQ;=JHY?JU]DWL4-7$;."9!*W5DCNFR:HEW;J"(;2=V@\X7:?
MO%N.DLVT:'<SS=6I034NVUQNC!;!44KJ)J;221+%0D<.,-?=^U=U(M:T6>KI
M:*NF`I:I.+2DX$MHRUXX$Y0D^(N/G&SA-;UIQ)M?N1O+>_-S.[QFS(#I"]YO
MLP+H&^)+Y[)J(1F/*JMVG^&B(DK1N1#M`2*%*4XJ?>[S;;,[3[BH]A+IZN];
M]JDE3-LMX8+J4F927UJ*$,ZY>%*R"1(@$$32MC]J[?;`J\^-^YK)+E;4S6Z5
M$#4D$STIRDE)EC(DPMW(/D??JUBB"A\3X_D@Y.YND92AX+QM:02`8V>*!DY/
M*5]!D9SY=B[&,2?SJ7=#T43*@R)NZ>MR&EGM5NNX[\VFQNB\62NV]4NK7KHJ
MSI]=`20`3H.G2N<TY&6)`C!O:NJ[.P:.RZ:J^5!#;"4_"%*S<7,$)2T`5$JP
MF`(W[A[QBK7$K!M=Q+"3$A;)H'\U;\DY"FR[3^3LIW%\>9OM_F]S'%-U8)I8
MPI(]Q@:M$T4"B()@(R$\\7UZ\982]0P$:^U-N,;6L[=O2YU:K4I;KIS==<5J
M<<,R3-2N9/OATA1*)0$-MNOU>_Z-8%$`R)QAT8\<3%>XH#L(AN/NW#?0!,3&
M4$CGPCS.739FBJX<KH-FZ)%%5UUU2(HHI)D,=15594Q4TR$*&XF,(``!UUI7
M"NI;71N7*XNMLT3*=2UN*2A"$_O*6LA*1S*B!Z8O0A;B@A`)5R`F?<(117D?
M@]%[Y>?)%>,Y!04C'25=+,B*;B':>02:J,2=0]HJ=OUZYMK?.7Y8Z"ZJM55O
M*U)K4+*5`%U;84DE)!=0VILR((F%%)X&4*(V]>5IZB:=>DX_$!]IP]1QA9H^
M28RS-O(1KQJ_8/$2+M'K)RDZ:N45-^Q5!=$QTE4S%#<!*(ZZ/MEUMEZH6KG:
M*ABJMSZ9MNM+2XVL<TJ22E7L,)CB%LK+;H*7$Y@X$>N<(Q=,_8\Q];&%'L:T
MT6<D$XH[<&<.JZ:F++O%63+O=$4*!.Y=`W=T'M`-]<W=S?-KV@[0=Q:3MCNY
MRXM[KK$,+:2S3=5K34N=)H%84G2"J8.&$CQP*O26:OKV55M(@%"02<<9`3,+
MH!@Z[[!L.WM_U:ZAF#E"-%=P]NX;?3OJDP3('&`8Y1IF1KU`XQQ[><E6<SLM
M9Q]4+)=K$>.:F?OB055AWD[+G9,B&*=XZ)'L5!32`0%0X`4!ZZN"%*.E."C&
MC=*]FU6]^Y5(5T*=I;BM(FK2A)49"8G@.<,^X4^HMQQY\#?C\?'EV>)XT&M#
M:QN-.=U,4?FU.;-"@P!TY<?&^)\ON?$[=O#[2[_>#6[5VZHHDH6](!0]XEZA
MS$,_9'<+;>_?F?[?<>7\J4%>M&D`N`RD=1Y'W<I$OR/[/?[0WV]P;]1_1K12
M03*8G#[7ED3CPAK6<.:O%;C79X.E9WSOCW%=KLL4G.P$%<)<T<_EH9:26ATI
M%HF5NL!VAY-N=#N$0_>$$-9@VXH:DI44\P"1#;O6[MM;;J6Z2]5S%/5.RTI<
MF"4F>(D.8.)PP,S#H$%"J@54H[E42*H40W[1(<`,4P"/T@.K#E(<X<H)5):3
M-E0F,)?MC/N&V^X;?3N&WZ]6R.47R,Y<8.XNV_<&WT[AM^O1(Y<8)&<I8Q75
M(I"+9^:LW..'YWJ48HDTD8ER4TNA55V2!P>IH`N8+FNVKY%"E7$I3*G*<!-L
M3<P@`\[>:.CHJKM'5.5Z*5;#%73.$/BWEN27`%?^46BC!TDR+BTG]TSA5LRU
M(KDZ-6L@RTSG.7#3C[H:%Q1ML32K-FV/F)V(AJ7#1Q;L]EY&8@6]?A64<LOY
ME*.9.->*5IBQ;QRY3+*I+%;))H@&X%+TX(_3>N3MH[I[_P"WE$^ES;X<IZJF
M:0NF<;UJ<6E:T+I%+IC_`$^FG^@I38TR!PAR[YZ=+9Z6[52@TTA!ZBEG2$``
M$ZB9:>),_7#5LN\@<:<H3TS,^'Y%]-XYL,!.0U=L+Z,<Q);&E3K];:L[GXE!
MZ5-TM7Y1_%JJ,'!RD^):B14"E`P:Y]_58:52^82TH>2`\-JTJB4XZM556&1_
ME'VQF[3WBW[@VQ^;VU3BJ1=6XA.H&1Z9"=29Y@F>/*427<0!WP/5?=W25D`0
M+OUVGWY>H]?=M_9TUZ.?IW!#7E9LA;`TJJJO5+]XNG'ZOLA%W8`;V[R($,HK
M#QO<<R7RP31X=ZO*7U*+1;S1\>N!.V0G#M6Z+./NTBW=B*35DBD4T>F=78O9
M]_M`?-[MO<6NX_F6W1NS<JZ1YZJW*VPT*@V5:PVE]26DMM71U#@T-I0D+I&W
M',-($P!#LKV7*.QL4S8=T]'4O2%23.<@N0P,I&1]!B4*,HM=8VZ6OI617%OE
M8MG759QV4%G;&M1RQW;6M1)SEWC87S!4SI9)+M^)=#XBHG$B?9]`C6A+80@2
M2D`>X`<A++("7*(H%/3IJ558$WU"14<Y#$#U3^N-M4,)2F`OM]H=P#MN)@^@
M!^G6:8S,52$-K"5XMF?OX"(E)WUK.$%1SSECCW>YZ^T*T867O;>]6RT51HTH
M*"^/B=\JVB95I.OYJ8?2JPD;QK9".,X?.E")D(`F#6^BUU;K8=0D%!YX893Q
MPEQGRQB*U]Y-D-7JHV[<'W*6MI=>M2D@-@HGX=4R23*0&G%1EG&B\</7BX0\
ME<UUS!]:)E"F3=YF@KV/K/?ZM#Q=2MLZL8R<;#$>Q-FFW\!)3BX`DQ)((-R+
M+F*D)R*G(F-[UHJV&>N?$B6(&,HT-M]^=B;FW"-NTJGV:EPZ4*=2$)6K(`3.
M:N'.8$/)YP6.6C<?UJ!9*K(L+-/N$YE1$QB?$-HQB+UO'JF*/5!PY4!0Q!W`
M_@[#N7<->6'ZHF]]PV'M!:MN61YUF@O-UZ-843FIIMHK#)EP6J1*>($=,[*I
M6W+@MY1DMML2Y\O?_C"38MXQT3)&'&]E96&34N\BUD5$U6KY`8N'EFJ[@C2%
MD8H$CK@F0"$!0QE`5,"G>4>WMUSSV#\BO:'O/Y:V=Y4-QJU]SJRF=<ZC;[99
MHJIM3B6J9QA)P#@0@J*P%)"@1*0FJ5VYKC2W=+:VDIHQ*8.$QSA=N*^-\LXO
MC)^*NZ;%M7Y`$7\-$EE@DWD9+"HJ#XP$:E58LVD@B8ICD(J8?%(!M@$QAUUE
MY#>R/F"[(V*Z6#NH:9O:SY;<HZ9-4*E^G>25!T)2G4PAMU,E2#DYC$#&$?=-
MSM-TJ$U=,C0X!)?\7JYQ@R_8>/<9E*%8Y'J$M,7U5O6QBI1FT=J-D4%Y-=*&
M*=1*88I@#9\!S&W2/L`]1'V:TO,7O7REV#O[;+1WAL5?<NZ3C%N535#+>IM*
M5U+B:8$JJ6Y:'=2E#2K#*>48K-3[@J+8MRW+;:82%:ID`$RF1ZR.'U0G'.3U
M,./OI\OL?,L]0>5W2.3&%D>UJ5H5/862+,:IK1:4Q'OW#RPPIF\B0DRW533`
MA^](^X#N`AKTCIZ-55J6U@1.8XF4^`GG]<0IOGN18-@.4Z;\W4:*H$)4VF:-
M0E-)42`")@RSEC"V9LY=8@P/QC?\M;J_EW&(654J%R1=5^-2DY^4B;VM"-ZN
MG$1*S]B@[?R*E@;?NCN$R@4QA[MB]1FC#KX81(.DRQ.7T]4+5YW;8[#MO^[+
MBM?Y*4-+04":E!S3IEC+'4)3(A%L5\V^./-+AWG+.\=4<C../M?K>5:UD")N
ME:2@IRV5FK4H\GD%I`,(NQNCO6CF#D%6:9RNVZAG0'(!B"7OU>Y3NTM0EE9F
MY//EZ3E"-9=[;>WEM&LW`RU4&QMLOAP.)DI:$-J+B1B9^&8SSPAL?I!Y,]-K
M(B><Q]/3#-NQ$A$#CL<JEM$5+QH3HOD[=\F@S/*7JZ@OY:#61\3PQ;[>,&_?
MN';FNK%>RE"JE04"/"!/*0Y^B7T$-GM+=NVMR%<K8##M.MLM?,:P1/4%A`!*
ME#`A7+&9QG.%-YN^L/Q-X)9$C\2Y)+?[MD1:+C[#.UC&L'$RRM0@I4#J1CJS
M24_/UZ,:/9-NF*S=DDHJY,ALH<I$SD,:M%:7:P!Q$DX8*.$Y9QO;Y[P;/V!7
MHM%T+SUP7(E#8"B@&1!5B",#.7I'..6CUK^7."N:F>N+N8^/]Q+:ZD;#$=!R
M[5TR6B;%5K&VRO8G;JO6F%<[KQ<HBU=I*%`!41724*HBHHF(&TX[0T[2T#[#
MPDYKGZ\.$<I]]]UV#=^YK5<;`^'V4T24K!P6A74=.E:#(A4B#RD002#'=!E'
M+V-L#8JG,M9=MT11<>4N#;RECLTVJ<C1BV[$4$4DDD2J.GT@^=+$0;-D$U7#
ME=0B:9#',`"S4)6MTI0"5$QW?=;I;K+:U72[.H:H&4@J4HR]``_B)P`XY1!Z
M[_,I<"&UD-$-ZCR*?P?BBG\U(T*KMV:B/B%)\>A!/[TULAF@@;N`#MDW`E`?
MW7=L72RFP5JTA84.IGH_%[I3^J(-/F5V`BO-.$5ZJ<+T]30"/3(:I^^7JB5+
M\>?%C\*_XS?YL0?X>O*/,?G+X:0^*^.^/\G^5/EOP//?G;SS^`\I\'XSXO[/
M;V_:TG?*57S7RO37UN4C.)9_OS:?]L?WI\XC^WI?'J$]66B6>N>&F4YP\@1V
MV^L=O;MK5$.XSX"<:%D\C$U"M1Y*5;P,>TA)"3=S;V9:5UA$H1;<\BI(2,\^
M;NFD+&MBMA,X=*)F(@CW'$-@TS.X6W:S=6R[A8K>M3=P?IU!HI<#2NH,4`.J
M:>#<U`#46ER_=C-3U+-(^FI?6&V$8J492`XDDD`2SQ,0U9,H>(LBO[!0\\N"
MVW#F5VU;9WV&IUZEY&3>1]?G:S<(I5],Q\'6',M5)QW7VZ:Y&:0I/HM=4B:A
MMRB/BQV\[I,^4[S5U6[.X%0RBVW5A=#<J=JK-?54KP"2BHJ!\K1S:"ID=-J7
MBPGC#NOVWJ#N3LY5EQ?HEN-NI4%%"7$H,P$%))D2`#Z,9C`QMO)*4QL^L=)C
M\3#`HT>L8ZA*S#1-:8EC(:`91;Z4(SA6,81LT2CF[)B*0$1(0I2%$-@U#/ZA
MO<S8W=GO':]R]O[K37:RHV[3LK=9R0\*FJ6IM<P%:PEQ!*3/3J$.79-I<L-H
M^3<8^7ID.:4)$@D)```2!RRAQF&>0E`Q7Q_C8Y_*E>7%H:S+,:NT276?*NG4
MN^5CP=G*G\,R:J>,F<RBB@`!#=`$>FNL?+/YN>SW8ORG4-OO5RZ^^6'*W10,
M)*WPXM9+:G`0$(1QU+4!PA$N]DN-UOZPRV0SAXCEGZ,8U_BU4I.;E"3*,FT?
M-"V`MAL3N$M#U-%L[6#XE")?0J].582#L[LFRY$Y,ITTS]0#INW?(EVVOUXN
MB]W4U8R_1N74U]6[3UXTMS,TL/4ZJ!P.NGXB6JE,M0"D@#4=G<=46U%IS4E7
M22G3@02!(JF#@#*67")-DMMAV'_:'ZMN@=-M>UJ"2F:B9^G,<9&([5.<C&-7
MW_I+^TNKC\*O9&!68_G3]L<+N*\>4?*7YBJ^4[(U3@;Q4G7*//<H]K%H8)3$
M"_?U^HVN<A%W\2\*JQ>A'2[!%P1-4ATC*)%$Q3`&VGC4NZ+*@HF%A($QZA'#
M-EH**X^8NHI:YEI]E5;4$I<2%)\(4K$$&?H!P]D9_7HQ]3L'>H]A&U8OKD+1
MW5BQSB>_/V]4C&<`T4N%7R;.1;&PE9QB#9HA)G90;,AU$R%$_P`,0QMS!OJM
MG<4[;'M9)EG/'"+^_-NH]N]S+5<;0TW3.*#2_P"FD)Q0LB>D`)!D!Z^.9CM2
MR1C>"RQ4%ZQ8?%22<BC(1\@U[0>P\F0#&0?-1,`E$4P5,4Q#`)%$S"4?;N',
M??+LQL_OQLFJV!O)*@RXX':=YOQ.TCR4Z4/HFH8XF:3)*@2#GAWO9[M5VVH;
MN+!`/3$Q+`F0B,:QX]S9QBF%+!`2+P((S@"#8H,#+P+],AB^"C9X9P50C=0P
M?9V<%.0/8FMOMMX?[T[1^:;R,;F>WAM&LJ'=F=5)%92A2Z-]/`5U*5?TEG$&
M:9$@E"M)!,C-7"R[A9Z=0V/FCB23(S.<I>GE#]N/N>&V98%ZA(-F\7;X$K?S
MIBV[P9NVS@!*UEHP%1%4&K@Y1(H0PF%!4.T1$#%$?5SRB>:NU>9?:=0U=6FZ
M#?\`;BV*NG03I6VN014-2.H-J5X2"9I/H(ADWNR/VAQ!2I*FUY'&0]!G]/=#
M/>5G_P!)TW_QU!_]F?Z\X_/X9>=S;1_^)9/_`-]1#IVR)[9J1S=5_P`AAJGY
MC/!YLD\$F63VC(7,OQ_RC6;6HLF3N41J5R,I0K*01[1-X'Q4U'N#]0#^&`1]
M@"'T#V)U#-8`K\7VS_SCCCS)6073M\:UH#JT+R')XS"5'0=,OXM)5/@,,8AE
MY>\P/G3T)."N,0E17L=BR%(XZMP"H8RHP'&`9AJT1<``^(9+LD*PJ'<'M$H@
M/0-U*DHE+O#H5),DZI\`,S]AB'=Z[P%=Y?[+;TJ*JFI6&5)FG4/EU9'&8PT$
M>PGC'0!Q]P>/'ST0WV/W3`D?..>%&7KU:D2I@FL%IR7C>W7V:2=AL`BX9+SP
M-1WZ@5``]P:0JZH#]Q*QEJ"?=(?;/WQT!MZPHVWV75;"E(>%EJ%J*9R*G&'%
MZC/'5*0/IB+3\K.&[#F@&^VZF!>O^'RE^W2ON3%-./X#]@B'O*C\5\GB-5-]
MM1#2VE6@,Z_F/K#5LG13&VUTO)JVBYA)UJE*1,BUQ?BYZ]JL=(1[L%6KR.:.
MZPS.*"A3)'\(`,42[AJ]25IL"'4J((/#U0U7Z2GNWF4-+7I2_3FO4"EQ(4"E
M#:B$R,Q+"0PR]9CS_F(<3XWQCS7PBOCNC56CFN^'J]8K>2J0S*`:V">9Y+GX
M5M,/X^+1:QYI,L4P20.L5,JBA$B=XF$-]%D=6Y0.%Q2EKGF<Y2$8/,?:;/:-
MZVT6NE8IBY2!2@TA*$J/4=3,A('B\(GAD!'5)SZX3T3G9@RM8KR;E2\XLHU7
MLT9DB7D*2YK3/S-2O0$JT:)6%U9XR38I0L5YHH]$W:GV+(D.8P`33?I*E=*^
MIQ"0HG"7N/W1UGW`V1;M_6!%FNU2[34"%AU:D%(20E)$EZL-/B/M]$<TG,[)
M_H\8&X3VWA)Q\91'(7/#6.4+!YWK]$@)>:9W]E84)*0M]HS8DTA4'Z;=DDHU
M4;0)WK$K42M_"(F([.&B;N-57H>><Z0X`S^P"7+&.:=^7CL_M;8E3L:Q--5U
M[0UI^8;:;4I"BN<UO``SP*9))^\QM?,<U_1L^6O-GGR__4=^)\L[Q^&\?\/O
MFG9X>W;X?F/[_M^[XWV_O_:TH2/Y[H_'+/[XC'YB[?[$_)ZCT/S_`*<M9E+H
MSE*>6K'U\(^CRL.Q0^LP%Z;[AO\`1L`B(_5IB`R,X](7`%)T$D3PP^GOB"7.
MMBL7JI<A;9PSQA/R\'P=P'8&"/,[*M;>*-5,VWQ@Y*\;\8Z/--Q^U7V"S4!L
MSM$P@/:*8=`1%RI(0FC0'GDI4\1X4*!D)B87P.!Q$I2,O2(A:[UU7W,W&YM"
MU.*;VC0+2FN=;.+SHQ%,A0E)(S4H3Q200/#.8E#"^*6U5K=*;X]IR52J,%&U
MNJ0*4"Q385V!B&J+*+BH<I4Q48LF+5`A$R)F```NHNWOVJ[<=RVBSW!LMMNR
MEF:C4,(6HG`GQR"^`S492$3A;GG;'3MTMK4IEAI(0A"3)*0!(2'JSYQ&1RQH
MM6H.1HB(J$,T@HYW5&3]PS9"O\.=^M*RZ"BX%<KKB03I(D*!2[``%]FOG[_4
M-[7[%[5=YJ#;>P;93VVUO;>8JW&F`0%/+JJMM:A,J*4Z64X$R`&&<XE3:E?5
MUMK*[B[K!?D)YS]DSC/'#UPX'C11\*3U(JK>RUFM6'(DCYT_<LWC<9621B&L
MV\9LY63CSJ+MHB.,1($D%%TTP7,7M3[S`8`[]\BWEX[)[V\OUHWKNW;%IN&Y
M'ZBHUU#[/46H-NE*?B,L`,9"1.,-7<]]K*:]NTC3Y"DR&E)`D#SECCZ3[(?S
M'1,;%-$F$6P91S%N':@S8-4&C9$-@`0(BW(DD3V>X->EUIL5KL%&BVV.G8H[
M:V)(:8;2TV!(#X4``G#.&LM]]Q6MTDJ/,S,?HE+VAL'L]VE1ML-ID"3C,DF9
M)]<8U'49QA5]_P"DO[2ZN/PJ]D859C^=/VQP:P&<L9\</S`64LP9BGS53'59
MY/9Q:V*R_`/))M")V:O66KQ\C(MX])=Z2+0E99'XE5--04$1%02B4HZ>3U.M
MZR)+>)\.'_"(X*I;_;-M>82HNMX7TK>FOJ$J7(D`K"DB8$S($S/HC'ZPV?<9
M\Y/4:P1$<:[*SRE"QU:Q%B%A9JP59U#S]TL62Y66<L(%THBB,FC&HV)JFHLF
M`I@N50H#^[,.KK=3NT-J>-0-)4,!QC+WEW%:M]]R+91[:=34M-E#>M'B"EJ5
M/``3DF<B<0>!XQV.<JK1E6AU.'L&/I08V(;N3QMJ<-XYD]>LTURHIQ<DFN[1
M<`T;`L4Z:@@7H=1/<0#KKS/\^^_^_':_8=)O+L[5BFLS3JV[FING;=>;2N71
M=UJ2I;:!B%%,@#)1PCT;VA26U^I3373X4I$A^]+#]N,)G`<N*)(XH7C+\G)O
M[FG`.864BBQAG+:RNC-#-B/`=D#X-J1\"A3N`5$@HG$VP&#;4%;9_40[17[R
M^.VKN>*A_N*;4Y1U-+T%+;KW"VMM+O4/A"'9A:R=*D**BGA"N_LRY-WGJ6\:
M:`KF#P`)F/7(>^$^X+P$L-SMEG!!0D*QK)8-58`-\,O)OI!F\3:IF$`!11LW
M8&.?WD`Q=P#NU#WZ6&SKV]W*W%W"::T;38M+E'KQT+>>J*=Y*4J,M73;94!@
M9:\^!WM[5%,BC9HL#5MG$\Q(_P"4?G<JS;\DZ;[@!ACX-_\`>LK\?HZ>S;21
MY^@%^=G;*QQI+++(_P#OWN1_B^K"<XIM?2O;;R4$E:G5F4L@$&'M<H\+LN0O
M''.&$9$B:J>3\7W.GMC*;`#:6EH5XG!/BB;H52-FOAURC[C)`.O>UE1;JVWP
M9(21,>T<8A7<EF3?-MUUE=D34TSB`2)R4I)T&4\=*I',99Q\W?B[C:\\B.0'
M&CB!.N'8P#G/1XQU6U43&)73V*4K8YA>&3`OC>(-?QWNN!_LD^$'WB8=2!6/
MI32JK&T2<+1!D?83'FSM"W7+<.[+;LM]Q2:5->HR4G4$:E@+44@B?A2)C#W1
M]&GF$V09<-N4K1LD1NU:<:<V-VR"1`(D@V0Q?94T$4B%Z%321*!0]P`&H_92
MI3PGBHKCTCW:E#>T+FVV)(%LJ$@#_P!!8`$<W'Y6GM*QYG;"!]U<"].@>Q+*
M8#MU'?[(;Z=&Y$D"G/\`!]PCF+RHH6$WQU6""NF$\<QUSR'[P$,TR!?J_P`0
M/S#%IRGF=W\JT1AR"D[/-6)X@X.VBJ=ES&:S"*M"J;=)9PK$,#68AW"B9#B1
M-%40`>P=9D#YBPBG:Q>P,O9C[H9=VN--M;S'JN=Z)9H/G2HK4#+0X@C5@"2!
MJ$S+W1IOKI\IL&<K^7>'K'@"\LLDU.A8UAZ%-W"#:O\`Y6=6DM]EK0ZC8"8>
M-6J$_P"71<VU%RJV`Z*2BQ2]QA'IBL],^Q;G2M.(.7N'W0G>8/=%DW1O&AJK
M"]\Q1L4Z6BX$J""OJ.*(!(`,@M.(F#C+*)<?S*&:<GT;CAQ]Q33I.2A:3F:U
MVE/)"\:X59A86M)KT&_@Z5*.D#I&-#2CV85>.&QA['7P!`,4Q"'*.E8Z=EVJ
M67""L9)Y^F<3+YF+[=;=M"AM]&IQFDK'#UEH5P2D$-$!))U%6J<T_#Z<&!3.
M9O2QP1Z0U@QEA:QU:U\M.1&'8*NW9RVKSF4RXCD.27C)6W,[?*O6)0H]%J;E
MJZ;MFJ#A-J=NBF9!)R=0RH[P8N:[V"Z=%(D^$>R1/V?7#!<OO:C;O9YRTVLH
M=W/6TB>II:)<Z@4E1*U*$D`'*1\1Q]4;&X?TB/N]/ZBFVWOW_#9MMO\`1M[_
M`*??I1T*_.\\.?MB*_ZG^Q<L.C_<DYX:O]#U_=';CZI^>,F83XJNXG""*HYU
MY`Y&H?&7#;U`P]T%><Q/W$.2R=X$-X"]?@&KYTW4$-DG2:1QW`HAIGT+#;KQ
M+ADA""KUREA]?U1W?W+O5RM&V.C:IB\W"H11L$?A6]J\4Y8$-I7(Y!4IPX#B
M#Q>H7#GC]CS`F/TP58U6**I89]4@>8W6\28%>7&[S2YMU7<I8Y@RBPBH8PI(
M>&B4>Q(H!@?J5/NEUS`)$ACD.7^/,SA<VKMNDVA86+!;!/I)FXO";CAD5K5S
M).`'X4R2,`(6#)>4<=8<ILOD+*EWJN/*/`MU'4O:KE-L*_!L4B$,H!5'L@JB
MF==4""":1!,JJ;[)"F,(!K&$.N*TLI*G=),AEAQ)X"%BY7.WVRB57W)]MBF1
M(E3ATC#U\>0&)X1!KG/-4[S$M\9D'$"-@Q!QU)`I0C#/%\JOPF1,OI-)%^[6
M<\:\165-!X:OO".2IDN=J;MHI'J=HQ?F[=_,+SO]O?+_`&7N72=YO,!>%U#%
M+9&:6DVW1J"*NO=:>J7PNI>!*F:4]=*5I"?&)G4)0;1W7O#=]%\AL6F72V%Q
MPZ[HX@A12K!2*1M<I@Z3J=41I\)2#.)*>$YL253%495:?Y#"S[Z9FW$M'/+`
M>:OEA?(/''9.VZ<F%U;%<;"\C4RK+/5OL"4=D4T$"E13FSR=]_\`97<SMG0T
MC"]OV:^*J7VV++1*0R*5A*B6FD,DZUJZ8U+=`\9FHR.$+]QVI^0KZ-.'5M2!
M+KA*EK5^)2U_B,\IY#`80^$GL'V>WIM[^@:[-"DK&I,_;Z#&A(C,S,7ZK%(P
M+>SI[=P``^OH(?K$-6*,E!'!46*"005&0U)^J.'#"M8K-U_,5Y/J=P@H:TU>
MQ\@^3T1.URQ1S*9@IN*>8XO"3N/E8J02<LWC58H;"10A@W`!]H`.GD[4/MV-
M/3`"<!,''`".&;#24MQ\QE91UC;+U&JHJ=2'4A23@O@01,X2CI[P;Z4'`OCQ
MEA+.&)\#1$#D-DX=O*Y(24[:;+'4ER^250<+TN"L,W(Q-=<@@L=-)9%+QFZ9
MA*B9,H[:;E17U=0@-N+FF4=36/M1L+;=Z_/[50-MW+45)(4HI259E*3@,S+#
M">$2'.V#5^T68O4&[QHY2,@Z;.D$W#=RBH42JHK(*@=-5)0H["4P"`Z1:^V6
MZZ4;MNN3#-10/HT.MN(2M#B")%*TJ!"A+F#$BH6MO%LD*&1Y<O=#?77$S`[J
M0\P-2B(;G[S,6DK+M8T1]HE!DB^*FFF(C]TNP>X-@UR17>0?RKW"ZKNS^V4)
M<<=+BFT558AG43,@-I?`0DG\"-*1DD`80NHW/?$-AH/JT`#ZH7&O5F#JL6VA
M*[&,8:*:%[6[&.;$;-T]_OG$I![E%5!ZF.83',/41$==-[6V5M?8UE9VYLNA
MIK98J?X&6$!*!SU<5D_O*)5S)A%<??J%=2J47'>9^AC2+/A7&URL+:UV:MH2
ML^S38)-9%1Y)HJ(DBW!W;$H)-7R+<W@.%#&^T0=Q'KN&HWWMY;NS'<;>=/W!
MWM96J_=M(&0R^IZI04"G6IQH!+3R$$)6K5BD@G,$80H4EZN-"T6:9>ELE1D`
M/Q"1SGPA4]AV,`#L([[#M[!'W[;]=M3EPA),Y89PQ['/IN<*<2YR/R1Q[@>M
MUK-*DU:[&-V;2UN<KIS=X)))6J1;0\A8WE=9KRJ4PZ*/A,R%1!<WA`3IMN*K
MJA;/14KP2AFT';S9EKO?]Q6Z@::O!6M1<!43-8(5@3(9F6&$._N51KV0*A::
M);HXDQ5+I79FJ6>(45702E:]88YS$S,:JNU50=(IOXYVHD8R1R*%`XB4P#L(
M:J%%"@M/Q"'75TM/74KE%5I"Z5U"D+221-*A(B8(.1X&&Y\:.#W%WAX%M+QM
MQ3&8O)>AA!MA(V;M<SYU\N!(E@_'-:)^<,CY?YLY[?!%/N\4>[NZ;9'JA]^6
MM6`AM[<V-M7:274[>I!3==25.$+<5J*9Z?C6H"1/V\XT?E/Z;G#KF?/0-MY!
MXC96NX5QFG%QUOB9FP5"S*0B3A1TG`R<M5Y2+<3$.DNLH9-%UXO@"J?PA)WF
MWO9JWJ?%DD8?;&KNCMWM#>:VWMR4:*BH;$@H%2"1.<B4$&7M^HQJUL])_P!/
M>Z5W&]2G>,M*-6\1LI5ACZ(BY"VP#6"1GI!G*SCA08&QQBLU*3$A'HJN7D@9
MT[6.F7O4,`;:O3<*Q*R2LE!&7IY_01J5?:O8-;34]&];FA3TH5TTI*DB:\RJ
M1\1GC-4SPRAR?(7B_@KE5C=7$V?,>Q&1*.9ZTE&D=)'>M'L/,,$%6S&:@9J+
M=L9F$EVJ"ZA"N&RZ9Q34.0W<0YBCB:J'&'>LT9+^AA?O^U;%NBW&U7VG3446
MH*`5,%)"=/A4D@@RF,#C.&GXQ](#T[\35>ZU.K\<JX\9Y$KK^HV^5M,S:K3:
M)"L28I"^A(^SS$XYF:TS="@3Q!BU6:BG:'>8VMARYUKJ];BR2,OIQ]4-BV=H
MNW=I8>IZ2V,Z*A!2HK*UJD2#X5+42G$<)'TRPCW?TD/3W_EI_)W\.T/_`"S^
M??YG?*7SEDGX'YZ^7_E;S_XKYS\S\?R#^&\/Q_`[.O9W==6_/U$]4_%^V<'^
MT7;[\N_*?R]/Y;\SU^GK7+J:-$_BY<,N$-^YS\GLU<;>1L*K<.%F1.77%2T5
MC&UJILMB:LC;[;B#/6-+1:9(TFI$%CGJ*+EXW?1KIBY468J)J(#X*RG[U(,M
M$W3/MF3I;>D<2/#IY<YY<Q@82-\[HO.V[XWU;+5W7;RVVUMKID*<<:J$%4U!
M("@`$\2$XG,S,:H7FOZGO*`A8CBCZ?:_'B$?[)GS3S9G_EYO%-G`@09**Q5"
M(HV&6=(D,)B%`SM$1#[1=M]LGR=L8']=]3A!PTB6/IG/#W1I-;S[D;F3IVS8
M3;FR"H5%<HITDF4PUH2K5F?QC"4N2M8C]+1A8+K#9PY]YDLO.#.$,X2E*Y'7
M1FE"<>\8R('\9(,=829"6L&79*;=CR117.<P`IX*:@`(85W$](T]*`V@YD9G
ME/A*<S*%.T=L$OUJ;UOFL=O-V!"DI<$J5L@J(T,8`F2@/$`G`>&<XDMDL1XR
MF7BDC,46KRL@JFBDJ^D(9BZ='2;IE102\95$QBHHI%`I"!L0A0V``#4)[A[#
M=G-W7=V_[IVY:KA>GQ_4>J&0ZXKT363I'()D!P$30Q<Z^E;2S3NJ0RE(2$ID
M$@#```8`#T1?#XGQK7Y-O,P5&JT1+,Q4%K)1T(P:/6WBIG15\%PDB51/Q$5#
M$-L/4IA#5=N=ANS6T;PSN';6VK/0WQ@$-OL4Z6W$3P\*DXC##T\8I47&X52=
M%0\M:?3"@@&W^7U`'^C4M\)1IDSBNB*18)`,(B(^W;I[NFK5)"B">$4D"<<1
M+[YP@L7Q6XVPF3G&;(?!.)XO,3N3E9ISE)A0JVUOSB8G&Z[.9DUK4C'DF5'T
MHT=*)+J"MW*)J&*(B`[:V%5#ZFRR5GI3&'`2A":VOMZGN:KRQ1L)NRRHET)&
MLE0D3.%[*7M*4OM[0`/<'LZ>P.FL1,S.%Q"=*0F<Y"+M4BZ#1!!H@@T00:((
M-$$&B"#1!!H@@T00:((-$$&B"/"E_P!W_AA_ZI=9$?\`:C^;[C":G_R:?_K_
M`/4F+U_[U'](_P#"?56_A5ZOOC8?_P!=G^?[HO2^^/\`RR_M-JQ6<93_`-TO
M^4??'HU;&6#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:(
*(-$$&B"#1!'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
